SC
JUNO

Sculptor Capital’s Juno Therapeutics, Inc. JUNO Stock Holding History

Sculptor Capital’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,000
Closed -$538K – 295
2017
Q3 		$538K Hold
12,000
– – ﹤0.01% 283
2017
Q2 		$359K Buy
+12,000
New +$296K ﹤0.01% 287
2016
Q1 		– Sell
-58,500
Closed -$2.57M – 478
2015
Q4 		$2.57M Hold
58,500
– – 0.01% 260
2015
Q3 		$2.38M Buy
+58,500
New +$2.57M 0.01% 295

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Sculptor Capital's JUNO Position: Q4 2017 in Review

Sculptor Capital sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 12,000 shares — an estimated $538K sold.

Sculptor Capital first reported a position in JUNO in Q3 2015 and held it in 4 quarters. The position peaked at $2.57M in Q4 2015. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • Sculptor Capital reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Sculptor Capital sold 12,000 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $538K.
  • Sculptor Capital first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 4 quarters.
  • Sculptor Capital's Juno Therapeutics, Inc. position peaked at $2.57M in Q4 2015.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Sculptor Capital's 13F filing for Q4 2017, filed 13 Feb 2018.